|
EIF3H expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.986400E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.494600E-01 |
| Normal-vs-Stage2 |
2.160400E-01 |
| Normal-vs-Stage3 |
9.793600E-01 |
| Normal-vs-Stage4 |
3.498800E-01 |
| Stage1-vs-Stage2 |
1.461020E-01 |
| Stage1-vs-Stage3 |
9.233200E-01 |
| Stage1-vs-Stage4 |
3.501200E-01 |
| Stage2-vs-Stage3 |
1.985760E-01 |
| Stage2-vs-Stage4 |
5.557700E-02 |
| Stage3-vs-Stage4 |
3.384000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.548800E-01 |
| Normal-vs-AfricanAmerican |
2.921800E-01 |
| Normal-vs-Asian |
7.223800E-01 |
| Caucasian-vs-AfricanAmerican |
3.684400E-01 |
| Caucasian-vs-Asian |
5.992600E-01 |
| AfricanAmerican-vs-Asian |
2.488600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.255200E-01 |
| Normal-vs-Female |
8.283400E-01 |
| Male-vs-Female |
3.759400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.155000E-01 |
| Normal-vs-Age(41-60Yrs) |
7.333800E-01 |
| Normal-vs-Age(61-80Yrs) |
7.756800E-01 |
| Normal-vs-Age(81-100Yrs) |
3.766800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.986800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.348000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.266200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.035800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.584600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.996400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.008200E-01 |
| Classical-VS-Follicular |
1.024610E-03 |
| Classical-VS-Other |
8.433000E-01 |
| Classical-VS-Normal |
4.703800E-01 |
| Tall-VS-Follicular |
9.405900E-04 |
| Tall-VS-Other |
8.556400E-01 |
| Tall-VS-Normal |
8.738300E-02 |
| Follicular-VS-Other |
2.172000E-01 |
| Follicular-VS-Normal |
2.603600E-02 |
| Other-VS-Normal |
7.166400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.765200E-01 |
| Normal-vs-N1 |
3.290400E-01 |
| N0-vs-N1 |
7.048800E-01 |
|
|
